- Info
- Insider Trading
- Financials
Universe Pharmaceuticals INC financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2025.
- Symbol
- UPC on Nasdaq
- Location
- Ji'an, Jiangxi, China
- Fiscal year end
- 30 September
- Latest financial report
- 29 Jan 2026
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 563,338 | -98% |
| Common Stock, Shares, Outstanding | 563,338 | +1214% |
Additional Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Accounts Receivable, after Allowance for Credit Loss, Current | $13,008,117 | +0.79% |
| Assets, Current | $53,603,675 | +3.8% |
| Property, Plant and Equipment, Net | $3,583,553 | +0.43% |
| Assets | $69,303,440 | +2% |
| Accounts Payable, Current | $1,669,785,000 | +33875% |
| Contract with Customer, Liability, Current | $40,708,000 | |
| Liabilities, Current | $13,173,930 | |
| Liabilities | $13,173,930,000 | -41% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $1,813,522 | |
| Retained Earnings (Accumulated Deficit) | $13,843,623 | |
| Stockholders' Equity Attributable to Parent | $56,129,510 | +23% |
| Liabilities and Equity | $69,303,440 | +2% |
| Common Stock, Shares Authorized | 2,000,000,000 | 0% |
| Common Stock, Shares, Issued | 563,338 | +1214% |
| Deferred Tax Assets, Valuation Allowance | $2,167,162,000 | -1.4% |
| Property, Plant and Equipment, Gross | $10,487,306 | +2.5% |
| Preferred Stock, Shares Authorized | 1,250,000 | |
| Preferred Stock, Par or Stated Value Per Share | 11.25 |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |